SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (124)12/9/1996 11:40:00 PM
From: T. Mann   of 6136
 
Hi Richard:

Thanks for the reply! Do not take me wrong. I do not short AGPH myself. I generally do not short good companies even if their stock price is too high. But we all have heard these arguments about next Amgens and BCHXF's. If only everything was always perfect. None of us really knows what are the manufacturing issues AGPH will be facing. 2mln tablets is only 200 kg of the chemical. This is small quantity. They will need to scale up. We also do not know the tox/efficacy data from phase II/III. We do not know if there will not be some "cure" by 98 or HMO's will not stop paying for AIDS treatment. Etc., etc.

Because everybody is so excited about AGPH with all the momentum players already in the stock, I think it looks now more like Iomega than AMGN. The market is not rational, it wants "great stories" and most of the stories are already in the price. AGPH may well be $200 a share in 98 but it will be $40 before it.

I may be a little too gloomy but I lost some money and optimism in 96 because I've seen great stocks falling through the floor (remember? goes up on rumor, etc.).

T.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext